Similar articles

Abstract: ObjectiveSafe and effective anticoagulation is essential for hemodialysis patients who are at high risk of bleeding. The purpose of this trial is to evaluate the effectiveness and safety of two-stage anticoagulation%29&ck%5B%5D=abstract&ck%5B%5D=keyword'>regional citrate anticoagulation (RCA) combined with sequential anticoagulation and standard calcium-containing dialysate in intermittent hemodialysis (IHD) treatment.
MethodsPatients at high risk of bleeding who underwent IHD from September 2019 to May 2021 were prospectively enrolled in 13 blood purification centers of nephrology departments, and were randomly divided into RCA group and saline flushing group. In the RCA group, 0.04 g/mL sodium citrate was infused from the start of the dialysis line during blood draining and at the venous expansion chamber. The sodium citrate was stopped after 3 h of dialysis, which was changed to sequential dialysis without anticoagulant. The hazard ratios for coagulation were according to baseline.
ResultsA total of 159 patients and 208 sessions were enrolled, including RCA group (80 patients, 110 sessions) and saline flushing group (79 patients, 98 sessions). The incidence of severe coagulation events of extracorporeal circulation in the RCA group was significantly lower than that in the saline flushing group (3.64% vs. 20.41%, P<0.001). The survival time of the filter pipeline in the RCA group was significantly longer than that in the saline flushing group ((238.34±9.33) min vs. (221.73±34.10) min, P<0.001). The urea clearance index (Kt/V) in the RCA group was similar to that in the saline flushing group with no statistically significant difference (1.12±0.34 vs. 1.08±0.34, P=0.41).
ConclusionsCompared with saline flushing, the two-stage RCA combined with a sequential anticoagulation strategy significantly reduced extracorporeal circulation clotting events and prolonged the dialysis time without serious adverse events.

局部枸橼酸钠抗凝在出血高危患者间歇性血液透析中的临床应用--一项前瞻性多中心随机对照研究

[1]ButurovicJ, GubensekJ, CerneD, et al., 2008. Standard citrate versus sequential citrate/anticoagulant-free anticoagulation during hemodialysis: a randomized trial. Artif Organs, 32(1):77-81.

[2]Buturovic-PonikvarJ, CerneS, GubensekJ, et al., 2008. Regional citrate anticoagulation for hemodialysis: calcium-free vs. calcium containing dialysate‍‍—‍a randomized trial. Int J Artif Organs, 31(5):418-424.

[3]Buturović-PonikvarJ, PernatAM, PonikvarR, 2005. Citrate anticoagulation during plasma exchange in a patient with thrombotic thrombocytopenic purpura: short heparin-free hemodialysis helps to attenuate citrate load. Ther Apher Dial, 9(3):258-261.

[4]DaugirdasJT, 1993. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol, 4(5):1205-1213.

[5]European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association, 2002. V.1 Haemodialysis and prevention of system clotting. Nephrol Dial Transplant, 17(S7):63-71.

[6]EvenepoelP, MaesB, VanwalleghemJ, et al., 2002. Regional citrate anticoagulation for hemodialysis using a conventional calcium-containing dialysate. Am J Kidney Dis, 39(2):315-323.

[7]EvenepoelP, DejagereT, VerhammeP, et al., 2007. Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding. Am J Kidney Dis, 49(5):642-649.

[8]FaguerS, Saint-CricqM, NogierMB, et al., 2017. Heparin-free prolonged intermittent hemodialysis using calcium-free citrate dialysate in critically ill patients. Crit Care Med, 45(11):‍1887-1892.

[9]GuéryB, AlbertiC, ServaisA, et al., 2014. Hemodialysis without systemic anticoagulation: a prospective randomized trial to evaluate 3 strategies in patients at risk of bleeding. PLoS ONE, 9(5):e97187.

[10]KhwajaA, 2012. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract, 120(4):c179-c184.

[11]LinT, SongL, HuangRW, et al., 2019. Modified regional citrate anticoagulation is optimal for hemodialysis in patients at high risk of bleeding: a prospective randomized study of three anticoagulation strategies. BMC Nephrol, 20:472.

[12]MoritaY, JohnsonRW, DornRE, et al., 1961. Regional anticoagulation during hemodialysis using citrate. Am J Med Sci, 242:32-43.

[13]RichtrovaP, RulcovaK, MaresJ, et al., 2011. Evaluation of three different methods to prevent dialyzer clotting without causing systemic anticoagulation effect. Artif Organs, 35(1):83-88.

[14]SchmitzM, JoannidisM, CzockD, et al., 2018. Regional citrate anticoagulation in renal replacement therapy in the intensive care station: recommendations from the renal section of the DGIIN, ÖGIAIN and DIVI. Med Klin Intensivmed Notfmed, 113(5):377-383 (in German).

[15]SwartzRD, PortFK, 1979. Preventing hemorrhage in high-risk hemodialysis: regional versus low-dose heparin. Kidney Int, 16(4):513-518.

[16]von BrechtJH, FlaniganMJ, FreemanRM, et al., 1986. Regional anticoagulation: hemodialysis with hypertonic trisodium citrate. Am J Kidney Dis, 8(3):196-201.

[17]ZarbockA, KüllmarM, Kindgen-MillesD, et al., 2020. Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically ill patients with acute kidney injury: a randomized clinical trial. JAMA, 324(16):1629-1639.